368 related articles for article (PubMed ID: 35347134)
21. Nestin may be a candidate marker for differential diagnosis between small duct type and large duct type intrahepatic cholangiocarcinomas.
Sasaki M; Sato Y; Nakanuma Y
Pathol Res Pract; 2024 Jan; 253():155061. PubMed ID: 38154357
[TBL] [Abstract][Full Text] [Related]
22. Immune cell atlas of cholangiocarcinomas reveals distinct tumor microenvironments and associated prognoses.
Xia T; Li K; Niu N; Shao Y; Ding D; Thomas DL; Jing H; Fujiwara K; Hu H; Osipov A; Yuan C; Wolfgang CL; Thompson ED; Anders RA; He J; Mou Y; Murphy AG; Zheng L
J Hematol Oncol; 2022 Mar; 15(1):37. PubMed ID: 35346322
[TBL] [Abstract][Full Text] [Related]
23. PLK1 and its substrate MISP facilitate intrahepatic cholangiocarcinoma progression by promoting lymphatic invasion and impairing E-cadherin adherens junctions.
Pan YR; Lai JC; Huang WK; Peng PH; Jung SM; Lin SH; Chen CP; Wu CE; Hung TH; Yu AL; Wu KJ; Yeh CN
Cancer Gene Ther; 2024 Feb; 31(2):322-333. PubMed ID: 38057358
[TBL] [Abstract][Full Text] [Related]
24. Prognostic analysis of radical resection for iCCA
Yu Z; Ni Q; Jia H; Gao H; Yang F; Zhu H; Liu F; Wang J; Zhou X; Chang H; Lu J
Front Oncol; 2022; 12():992606. PubMed ID: 36479069
[TBL] [Abstract][Full Text] [Related]
25. DKK1 drives immune suppressive phenotypes in intrahepatic cholangiocarcinoma and can be targeted with anti-DKK1 therapeutic DKN-01.
Jarman EJ; Horcas-Lopez M; Waddell SH; MacMaster S; Gournopanos K; Soong DYH; Musialik KI; Tsokkou P; Ng ME; Cambridge WA; Wilson DH; Kagey MH; Newman W; Pollard JW; Boulter L
Liver Int; 2023 Jan; 43(1):208-220. PubMed ID: 35924447
[TBL] [Abstract][Full Text] [Related]
26. An Immunohistochemical Analysis of Osteopontin and S100 Calcium-binding Protein P is Useful for Subclassifying Large- and Small-duct Type Intrahepatic Cholangiocarcinomas.
Yoshizawa T; Uehara T; Iwaya M; Nakajima T; Shimizu A; Kubota K; Notake T; Kitagawa N; Masuo H; Sakai H; Hayashi H; Tomida H; Yamazaki S; Hirano S; Ota H; Soejima Y
Am J Surg Pathol; 2024 Jun; 48(6):751-760. PubMed ID: 38584480
[TBL] [Abstract][Full Text] [Related]
27. Anti-PD-1 in Combination With Trametinib Suppresses Tumor Growth and Improves Survival of Intrahepatic Cholangiocarcinoma in Mice.
Wabitsch S; Tandon M; Ruf B; Zhang Q; McCallen JD; McVey JC; Ma C; Green BL; Diggs LP; Heinrich B; Greten TF
Cell Mol Gastroenterol Hepatol; 2021; 12(3):1166-1178. PubMed ID: 34033968
[TBL] [Abstract][Full Text] [Related]
28. Molecular profiling of intrahepatic cholangiocarcinoma: the search for new therapeutic targets.
Oliveira DV; Zhang S; Chen X; Calvisi DF; Andersen JB
Expert Rev Gastroenterol Hepatol; 2017 Apr; 11(4):349-356. PubMed ID: 28162004
[TBL] [Abstract][Full Text] [Related]
29. Intrahepatic cholangiocarcinoma: Tumour heterogeneity and its clinical relevance.
Komuta M
Clin Mol Hepatol; 2022 Jul; 28(3):396-407. PubMed ID: 35032970
[TBL] [Abstract][Full Text] [Related]
30. A Mouse Model of Cholangiocarcinoma Uncovers a Role for Tensin-4 in Tumor Progression.
Di-Luoffo M; Pirenne S; Saandi T; Loriot A; Gérard C; Dauguet N; Manzano-Núñez F; Alves Souza Carvalhais N; Lamoline F; Cordi S; Konobrocka K; De Greef V; Komuta M; Halder G; Jacquemin P; Lemaigre FP
Hepatology; 2021 Sep; 74(3):1445-1460. PubMed ID: 33768568
[TBL] [Abstract][Full Text] [Related]
31. Overexpression of PDZK1IP1, EEF1A2 and RPL41 genes in intrahepatic cholangiocarcinoma.
Yang G; Zong H
Mol Med Rep; 2016 Jun; 13(6):4786-90. PubMed ID: 27082702
[TBL] [Abstract][Full Text] [Related]
32. Novel microenvironment-based classification of intrahepatic cholangiocarcinoma with therapeutic implications.
Martin-Serrano MA; Kepecs B; Torres-Martin M; Bramel ER; Haber PK; Merritt E; Rialdi A; Param NJ; Maeda M; Lindblad KE; Carter JK; Barcena-Varela M; Mazzaferro V; Schwartz M; Affo S; Schwabe RF; Villanueva A; Guccione E; Friedman SL; Lujambio A; Tocheva A; Llovet JM; Thung SN; Tsankov AM; Sia D
Gut; 2023 Apr; 72(4):736-748. PubMed ID: 35584893
[TBL] [Abstract][Full Text] [Related]
33. Molecular and radiopathologic spectrum between HCC and intrahepatic cholangiocarcinoma.
Jeon Y; Kwon SM; Rhee H; Yoo JE; Chung T; Woo HG; Park YN
Hepatology; 2023 Jan; 77(1):92-108. PubMed ID: 35124821
[TBL] [Abstract][Full Text] [Related]
34. Crenigacestat blocking notch pathway reduces liver fibrosis in the surrounding ecosystem of intrahepatic CCA viaTGF-β inhibition.
Mancarella S; Gigante I; Serino G; Pizzuto E; Dituri F; Valentini MF; Wang J; Chen X; Armentano R; Calvisi DF; Giannelli G
J Exp Clin Cancer Res; 2022 Nov; 41(1):331. PubMed ID: 36443822
[TBL] [Abstract][Full Text] [Related]
35. Different iron-handling in inflamed small and large cholangiocytes and in small and large-duct type intrahepatic cholangiocarcinoma.
Mancinelli R; Cutone A; Rosa L; Lepanto MS; Onori P; Pannarale L; Franchitto A; Gaudio E; Valenti P
Eur J Histochem; 2020 Oct; 64(4):. PubMed ID: 33131269
[TBL] [Abstract][Full Text] [Related]
36. YAP1 activation and Hippo pathway signaling in the pathogenesis and treatment of intrahepatic cholangiocarcinoma.
Ko S; Kim M; Molina L; Sirica AE; Monga SP
Adv Cancer Res; 2022; 156():283-317. PubMed ID: 35961703
[TBL] [Abstract][Full Text] [Related]
37. The Tumor Microenvironment Drives Intrahepatic Cholangiocarcinoma Progression.
Mancarella S; Serino G; Coletta S; Armentano R; Dituri F; Ardito F; Ruzzenente A; Fabregat I; Giannelli G
Int J Mol Sci; 2022 Apr; 23(8):. PubMed ID: 35457006
[TBL] [Abstract][Full Text] [Related]
38. Fragile X mental retardation protein in intrahepatic cholangiocarcinoma: regulating the cancer cell behavior plasticity at the leading edge.
Carotti S; Zingariello M; Francesconi M; D'Andrea L; Latasa MU; Colyn L; Fernandez-Barrena MG; Flammia RS; Falchi M; Righi D; Pedini G; Pantano F; Bagni C; Perrone G; Rana RA; Avila MA; Morini S; Zalfa F
Oncogene; 2021 Jun; 40(23):4033-4049. PubMed ID: 34017076
[TBL] [Abstract][Full Text] [Related]
39. Molecular portraits of patients with intrahepatic cholangiocarcinoma who diverge as rapid progressors or long survivors on chemotherapy.
O'Rourke CJ; Salati M; Rae C; Carpino G; Leslie H; Pea A; Prete MG; Bonetti LR; Amato F; Montal R; Upstill-Goddard R; Nixon C; Sanchon-Sanchez P; Kunderfranco P; Sia D; Gaudio E; Overi D; Cascinu S; Hogdall D; Pugh S; Domingo E; Primrose JN; Bridgewater J; Spallanzani A; Gelsomino F; Llovet JM; Calvisi DF; Boulter L; Caputo F; Lleo A; Jamieson NB; Luppi G; Dominici M; Andersen JB; Braconi C
Gut; 2024 Feb; 73(3):496-508. PubMed ID: 37758326
[TBL] [Abstract][Full Text] [Related]
40. Epigenetic dysregulation-mediated COL12A1 upregulation predicts worse outcome in intrahepatic cholangiocarcinoma patients.
Tang Z; Yang Y; Zhang Q; Liang T
Clin Epigenetics; 2023 Jan; 15(1):13. PubMed ID: 36694230
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]